Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000905148-25-001831
Filing Date
2025-05-16
Accepted
2025-05-16 16:51:38
Documents
1
Period of Report
2025-05-14

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 3817
  Complete submission text file 0000905148-25-001831.txt   5508
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Ekman Lars (Reporting) CIK: 0001376117 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35676 | Film No.: 25960143

Mailing Address 77 SIR JOHN ROGERSON'S QUAY, BLOCK C GRAND CANAL DOCKLANDS DUBLIN 2 L2 D02 VK60
Business Address 77 SIR JOHN ROGERSON'S QUAY, BLOCK C GRAND CANAL DOCKLANDS DUBLIN 2 L2 D02 VK60 011-353-1-236-2500
PROTHENA CORP PUBLIC LTD CO (Issuer) CIK: 0001559053 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)